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The combination of CHK1 inhibitor with G-CSF
overrides cytarabine resistance in human acute
myeloid leukemia
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Cytarabine (AraC) represents the most effective single agent treatment for AML. Never-
theless, overriding AraC resistance in AML remains an unmet medical need. Here we show
that the CHK1 inhibitor (CHK1i) GDC-0575 enhances AraC-mediated killing of AML cells
both in vitro and in vivo, thus abrogating any potential chemoresistance mechanisms
involving DNA repair. Importantly, this combination of drugs does not affect normal long-
term hematopoietic stem/progenitors. Moreover, the addition of CHK1i to AraC does not
generate de novo mutations and in patients’ samples where AraC is mutagenic, addition of
CHK1i appears to eliminate the generation of mutant clones. Finally, we observe that per-
sistent residual leukemic cells are quiescent and can become responsive to the treatment
when forced into cycle via granulocyte colony-stimulating factor (G-CSF) administration. This
drug combination (AraC+CHK1i+G-CSF) will open the doors for a more efﬁcient treatment of
AML in the clinic.
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Despite increased understanding of the pathogenesis andbiology of AML, patient outcomes remain poor, with amedian survival of ~1 year with standard treatment. At
present, Cytarabine (AraC) remains the single most effective
cytotoxic agent available for the treatment of AML, which pro-
vides high early remission rate, especially in younger patients1.
However, most AML patients relapse and succumb to their dis-
ease1, 2. Furthermore, elderly patients (>60 years old) cannot
tolerate high-dose therapy, and current treatment protocols show
an especially poor drug response in these patients. Thus, identi-
fying strategies for overcoming AraC resistance and enhancing its
efﬁcacy remains as a high unmet clinical need.
AraC is a DNA nucleoside analog, which exerts its cytotoxic
effects by disrupting normal DNA synthesis through direct
incorporation in extending DNA strands. As yet, a few
mechanisms of AraC resistance have been described, including
deregulation of AraC metabolism3–5 and cell quiescence, but one
of the most critical mechanisms of resistance is through the DNA
damage response (DDR)6–9. This is an adaptable response to
genomic DNA damage, which includes cell cycle checkpoints,
DNA repair, and apoptosis10. Cell cycle arrest, via checkpoint
activation, is a crucial task that permits repair of DNA lesions and
triggers apoptosis when damage is irreparable, thereby preserving
genomic integrity. This function is largely carried out by one
critical component of the DDR, the Checkpoint kinase 1 (CHK1),
which is activated when replication inhibitors, including cytar-
abine6–9, 11, cause DNA polymerases to stall but allow DNA
helicases to advance, creating regions of single-stranded DNA.
The latter causes the activation of the ataxia telangiectasia
mutated and Rad3-related (ATR) kinase12, 13, which stimulates a
phosphorylation cascade, activating CHK1, which in turn phos-
phorylates CDC25A, leading to CDC25A degradation and cell
cycle arrest14.
In AML, a recent report even suggested that expression and/or
protein level of CHK1 was associated with poor risk outcome15.
Thus, over the past decade, literature has expanded in support of
Fig. 1 CHK1i enhances the cytotoxicity of AraC in different AML cell lines in vitro and in vivo. a Percentage of cell metabolic activity in four AML cell lines
after 1-day treatment with AraC (A) and AraC+CHK1i (A+C) normalized on the untreated (UT) control. (UT n= 3; C n= 3; A n= 3; A+C n= 3). b
Percentage of apoptosis with the same cell lines and treatment conditions as in a. (UT n= 3; C n= 3; A n= 3; A+C n= 3). c Percentage of apoptotic cells as
in b, but the cell lines were seeded on an irradiated MS5 stromal layer. (UT n= 3; C n= 3; A n= 3; A+C n= 3). d Treatment regimen for AraC and CHK1i
with U937-Luc and HL60-Luc, in vivo. e In vivo bioluminescence imaging (BLI) 15 days after Luc-marked cell injection under different treatment conditions
(upper panel U937; lower panel, HL60). f Kinetics of tumor proliferation by BLI signal quantiﬁcation, up to 15 days after U937-Luc injection (left panel) and
30 days after HL60-Luc injection (right panel). n= 3 animals per cohort. g Percentage of U937-Luc cells in the bone marrow of the transplanted mice
3 days post treatment (D15) (left panel) and HL60-Luc (D30) (right panel). Each dot represents an individual mouse. (UT n= 3; A n= 3; A+C n= 3). *p<
0.05, **p< 0.001, ***p< 0.001, ****p< 0.0001
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Fig. 2 CHK1i enhances AraC efﬁcacy to kill primary AML samples in vitro, but does not increase its effect on L-LTC-ICs depletion. a Scheme of AML short-
term culture (STC) and long-term culture (LTC) analysis, using different treatment conditions. Three independent LTC-IC/LDA assays were performed in
duplicate each time. b Percentage of AML survival after treatment, using counting beads, and normalizing to the untreated condition. (UT n= 3; A n= 3;
A+C n= 3; NS= not signiﬁcant). c L-LTC-IC frequency of AML subjected to 1 week of treatment, 4 weeks of LTC in a limiting dilution assay (LTC-LDA) and
2 weeks in methylcellulose. (UT n= 3; A n= 3; A+C n= 3; NS= not signiﬁcant). d Cell cycle analysis of four AML samples 1 week after treatment, looking
at Ki67/DAPI expression. (UT n= 3; C n= 3; A n= 3; A+C n= 3). Statistical test here related to cells in G0. *p< 0.05
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targeting CHK1 to shorten the opportunity for lesion repair and
thereby enhance the effect of genotoxic agents, including ionizing
radiation, alkylating agents, nucleoside analogs, and topoisome-
rase inhibitors. Thus, inhibition of CHK1 function, using either
gene depletion or selective small chemical inhibitors, has been
shown to potentiate cell killing in a wide range of tumors. In
many of these studies, although not all, the degree of sensitization
was greater in tumor cells deﬁcient for TP53 than in their wild-
type counterparts9, 16–20. Recent reports further suggest that
pharmacological suppression of CHK1 enhances the efﬁcacy of
conventional genotoxic agents, most importantly AraC, lending
support for the deployment of CHK1 inhibitors (CHK1i) in
combination therapy21–24.
Here we use GDC-0575, an orally bioavailable CHK1 inhibitor
with an IC50 of 1.2 nM. We show that this CHK1 inhibitor in
combination with AraC enhances the killing of primary AML
cells ex vivo by inducing apoptosis. Using an in vivo xenograft
model, we conﬁrm the enhancing effect of CHK1 inhibition with
AraC using both AML cell lines and human primary AML cells.
Remarkably, we demonstrate that CHK1i+AraC therapy does not
affect the normal long-term HSPC compartment. Moreover, it
has been recently described that AraC treatment can also induce
the formation of de novo mutations in AML patients25. Here we
provide evidence in our in vivo model that AraC+CHK1i therapy
does not create new mutations, and that CHK1i prevents the
survival of AraC-induced mutagenic clones. Finally, we observe
that the persistent residual leukemic cells are quiescent and can
become sensitive to the combination treatment by inducing their
entry into the cell cycle via the use of granulocyte colony-
stimulating factor (G-CSF). Our data provide a safe way to
override concertedly both DNA repair- and cell quiescence-
mediated resistance to AraC therapy in AML.
Results
CHK1i GDC-0575 structure and selectivity. The novel CHK1
inhibitor GDC-0575 (see structure, Supplementary Fig. 1) has
been tested for its selectivity against CHK1 and more than 450
kinases and disease-relevant mutant variants using the KINO-
MEscan assay (see kinase selectivity proﬁle, Supplementary
Table 1).
CHK1i GDC-0575 enhances the cytotoxicity of AraC in vitro.
Although CHK1i have been already described in vitro to sensitize
AML cell lines to DNA-damaging agents18, 20–22, 24, the identi-
ﬁcation of selective inhibitors that may decrease the side effects,
and be efﬁcacious against the large heterogeneity present in AML
patients, remains a big challenge.
We tested here the effect of GDC-0575 in combination with
AraC on a few established AML cell lines. First, we showed that
AraC (A) at 500 nM for 24 h induced cellular DNA damage based
on γH2Ax positivity using either immunoﬂuorescence (IF)
or FACS analysis (Supplementary Fig. 2A, B respectively), which
in turn activated CHK1 (Ser345 phosphorylation) (Supplemen-
tary Fig. 2A). We conﬁrmed the activation of CHK1 mediated by
AraC treatment by western blot (WB) showing an increase in the
auto-phosphorylation of CHK1 at Ser296 (Supplementary Fig. 2C)
and inhibition of CDC25A phosphatase activity (increase in
CDC25A inactivate phosphorylated form) leading to an accu-
mulation of the catalytically inactive Tyr15-phosphorylated CDK2
(Supplementary Fig. 2D). We next validated that GDC-0575 at
100 nM blocked the activation of CHK1 induced by AraC via
decrease in the level of Tyr15-phosphorylated CDK2 (Supple-
mentary Fig. 2D). Next, we tested CHK1i (C) toxicity by treating
the AML cells with 100 nM GDC-0575 for 24 h and found that it
had no impact on viability compared to the untreated control
(UT), as illustrated by the XTT metabolic assay (Fig. 1a). When
combining AraC with CHK1i (A+C), we observed a signiﬁcant
reduction in cell viability (Fig. 1a) and an increase in apoptosis
(Fig. 1b) in all AML cell lines. Interestingly, the effect of CHK1i
was even more pronounced when culturing the AML cells on top
of the mesenchymal stromal layer MS5, which is known to reduce
AraC-induced AML apoptosis26 (Fig. 1c). We conﬁrmed this data
using a lower dose of AraC (100 nM) (Supplementary Fig. 3A), a
short hairpin RNA against Chk1 (KD Chk1) (Supplementary
Fig. 3B) and an inhibitor against ATR (ATRi), which is upstream
of CHK1 (Supplementary Fig. 3C). As expected, ATRi plus
CHK1i had no additive effect on AML-induced apoptosis.
CHK1i increases the effect of AraC on AML cell lines in vivo.
In order to investigate whether the effect of A+C observed in vitro
in AML cell lines could be conﬁrmed in vivo, we generated two
stable luciferase-expressing AML cell lines (HL60-Luc and U937-
Luc) and monitored their viability post treatment by biolumi-
nescence imaging (BLI), a previously described non-invasive
technique for in vivo studies27. We injected 2 million U937-Luc
or HL60-Luc cells into NOD/Scid gamma IL2Rγnull (NSG) mice
and followed the treatment regimen as illustrated in Fig. 1d. We
monitored the engraftment kinetics and initiated treatment of the
mice when they reached 1% engraftment. Strikingly, at day 15
(U937-Luc) or 30 (HL60-Luc) post injection, a signiﬁcant
decrease in the expansion of AML was observed when mice
received AraC alone, but an almost complete eradication of the
leukemic burden was detected when co-treating with AraC and
CHK1i, as revealed by BLI for mice transplanted with U937-Luc
cells (Fig. 1e). The quantiﬁcation of the luminescent signal is
illustrated in Fig. 1f (left panel, U937-Luc; right panel, HL60-Luc)
and conﬁrmed by FACS analysis on the BM cells at the time of
killing (Fig. 1g; left panel, U937-Luc; right panel, HL60-Luc).
All together, these results show that CHK1 inhibition enhances
the efﬁcacy of AraC for the treatment of AML cell lines in vivo.
CHK1i increases AraC response on primary AML cells in vitro.
Next, we investigated whether the combination of A+C was
beneﬁcial not only in AML cell lines, but also in primary AML
in vitro. We tested six samples representing different cytogenetic
risk groups (Supplementary Table 2). We cultured them on the
murine stromal cell line MS5 in hypoxic conditions, as previously
described28 and treated them for 1 week with 500 nM AraC and/
or 100 nM Chk1i (Fig. 2a). We saw a signiﬁcant decrease in AML
survival when using the co-treatment (Fig. 2b). Speciﬁcally, we
noticed a stronger clearance of the growing cells on top of the
stroma after A and A+C treatment, leaving the quiescent cell
cluster underneath it unaffected. We conﬁrmed this by showing a
signiﬁcant increase in the percentage of quiescent cells (G0) by
Ki67/DAPI staining after both A and A+C treatment (Fig. 2d). In
order to investigate whether the co-treatment was also affecting
the leukemic long-term culture-initiating cells (L-LTC-IC) and
not only the leukemic blasts, we collected the surviving cells after
1 week of treatment and seeded them at limiting dilution in
a long-term culture assay, as previously described28. We kept the
cells on irradiated MS5 changing the medium every week and
after 4 weeks, cells were seeded on methylcellulose for an extra
2 weeks. At the end of the assay, we counted the colonies and
calculated the L-LTC-IC frequency using an online web tool
(http://bioinf.wehi.edu.au/software/elda/index.html). In general,
L-LTC-IC frequency remained similar or decreased with A and/
or A+C treatment compared to untreated controls, indicating that
the residual non-affected quiescent cells were not enriched in L-
LTC-ICs (Fig. 2c). For AML patients 1, 4, and 6, a signiﬁcant
proportion of L-LTC-IC was actually sensitive to AraC treatment
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alone and the addition of CHK1i did not affect the L-LTC-IC
frequency (Fig. 2c). For the other three AML samples (2, 3, and
5), no signiﬁcant decrease in frequency in L-LTC-IC was
observed after A±C treatment.
In summary, the addition of CHK1i to AraC treatment
enhances the clearance of proliferating primary AML cells as a
bulk population in vitro, but it does not signiﬁcantly increase L-
LTC-ICs elimination, over AraC treatment alone.
CHK1i plus AraC treatment delays AML relapse in vivo. We
next tested the effect of A+C combination on primary AML
samples in vivo using the NSG xenograft mouse model. We
studied the effect of chemotherapy at medium (ME= 50–60%)
and high engraftment (HE= ~90–100%) levels, which would
resemble different stages of leukemia progression in humans. The
treatment regimen differed for the two groups: ME mice were
treated for 1 week, whereas HE mice received two courses of 1-
week treatment separated by 1-week rest, according to the
treatment regime depicted (Fig. 3a). Patient samples from dif-
ferent cytogenetic risk groups were tested (Supplementary
Table 2). Bone marrow aspirates of mice transplanted with
human AML cells were analyzed to monitor their engraftment
Fig. 3 CHK1i enhances the cytotoxicity of AraC in different primary AML models in vivo and reduces mutagenic potential. a Scheme of treatment regimen
for AML patient samples starting with medium engraftment (ME) and high engraftment (HE). b Percentage of human cells in the bone marrow of mice
transplanted with four primary AML patient samples. The treatment started at ME (gray area) and the analysis was performed on BMs of killed mice
1 week post treatment. Each dot represents an individual mouse. (AML5 UT n= 5; C n= 5; A n= 5; A+C n= 6; AML6 UT n= 5; C n= 6; A n= 5; A+C n= 5;
AML7 UT n= 3; C n= 3; A n= 4; A+C n= 4; AML8 UT n= 3; C n= 0; A n= 4; A+C n= 4; total number of mice= 67). c Same as in b but the treatment
started at HE (gray area). (AML5 UT n= 5; C n= 3; A n= 5; A+C n= 6; AML6 UT n= 3; C n= 3; A n= 6; A+C n= 6; AML7 UT n= 3; C n= 3; A n= 3; A+C
n= 4; AML9 UT n= 3; C n= 5; A n= 5; A+C n= 4; total number of mice= 67). d Sickness curves monitoring AML6-injected mouse under different
treatment conditions at various time points. Mice were euthanized when a 20% reduction of body weight was reached (UT n= 3; C n= 3; A n= 4; A+C n
= 4). We used the Gahan–Breslow–Wilcoxon for statistical analysis. e Secondary transplantation of hCD45/CD33+ cells, pooled from AML6-injected mice
1 week post treatment. Each dot represents an individual mouse (UT n= 4; C n= 4; A n= 3; A+C n= 4). f 3D plots showing the changes in the mutation
spectrum for each patient. Mutations present at D0 sample were compared to UT, A, C and A+C mice. *p< 0.05; ****p< 0.00005 and ns: non-signiﬁcant
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level (9–11 weeks after injection) and their viability after treat-
ment (1 week post treatment). After treatment at ME level, we
observed in UT and C-treated mice, an increase of the AML
burden compared to pre-treatment level (gray zone in Fig. 3b),
and a signiﬁcant decrease in A-treated mice (Fig. 3b) for three out
of the four patients tested. The addition of CHK1i to AraC
treatment in these three samples signiﬁcantly decreased leukemic
engraftment even further. This was not the case for patient
AML5, which appeared to be insensitive to AraC. Similar results
were obtained when starting the treatment when engraftment
level had reached a higher baseline level (HE) (Fig. 3c). A
remarkable example of AML reduction when using the co-
treatment could be observed by FACS analysis, with a decrease of
human engraftment in mouse BM from ~90% before treatment to
3.5% post treatment (see Supplementary Fig. 4A, patient AML9).
Here the analysis of the spleens clearly showed a drastic reduction
in size speciﬁcally in the co-treatment group (Supplementary
Fig. 4C). Moreover, we analyzed the AML engraftment levels in
the BMs also by immunohistochemistry (CD45+ IHC) and
checked the cell cycle status of the resistant cells by Ki67 staining
(Supplementary Fig. 4B, AML9). It was clear that the few
remaining human cells, after the co-treatment, were quiescent.
Similar results were obtained with patient AML6 (Supplementary
Fig. 4E). In addition to the reduction in disease burden, we detect
a strong delay in leukemic relapse, as suggested by the percentage
of healthy mice over time (Fig. 3d, AML6 and Supplementary
Fig. 4D, AML9).
The next question we addressed was whether residual surviving
cells were enriched in LICs. To determine this, we performed
secondary transplantation assays, retrieving cells from AML6-
transplanted primary mice, pooling them by condition and
injecting the same number of cells into secondary mice. There
was a signiﬁcant reduction in the level of human engraftment in
A+C-treated mice, but not A or C-treated alone (Fig. 3e),
indicating that in vivo the single treatment was sparing quiescent
AML cells, which contain LICs activity.
Finally, it has been reported that AraC treatment can induce de
novo mutations in AML patients25. To test whether the addition
of CHK1i could have a similar effect, we performed whole-exome
sequencing on three primary AML patient samples (Supplemen-
tary Table 3) before and after transplantation in mice and 1-week
after the last treatment (Supplementary Table 4). We saw that
adding CHK1i to AraC treatment did not generate new mutations
compared to Day 0 and/or to the UT samples (Fig. 3f and
Fig. 4 CHK1i plus AraC treatment does not affect human hematopoiesis derived from cord blood in vivo. a Treatment regimen for mice transplanted with
hCB CD34+ cells. b Percentage of human cells in the BM aspirates of hCB-transplanted mice 1 week post treatment. Each dot represents an individual
mouse (UT n= 5; C n= 6; A n= 6; A+C n= 6. ns= not signiﬁcant. Total number of mice= 23). c Percentage of HSPCs (Lin−CD34+CD38−) in the BM
aspirates of hCB-transplanted mice 1 week post treatment. The analysis was performed on the same mice as in b. d Same as in c, but percentage of HPCs
(Lin−CD34+CD38+). e Same as in b but at 8 weeks post treatment when mice were killed for analysis. f Same as in c but 8 weeks post treatment. g Same as
in d but 8 weeks post treatment. h Secondary transplantation of hCD45+ cells, pooled from hCB-injected mice 1 week post treatment. Each dot represents
an individual mouse (UT n= 4; C n= 4; A n= 4; A+C n= 4). *p< 0.05 and ns= non-signiﬁcant
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Supplementary Fig. 5). Importantly, we noticed that in one
patient (AML6) where AraC had mutagenic effects (Fig. 3f and
Supplementary Fig. 5), the addition of CHK1i prevented the
survival of these new mutated clones, thus averting the
acquisition of new driving mutations, a signiﬁcant contributor
to relapse in AML.
Taken together, these data suggest that CHK1 inhibition
enhances the killing effect of AraC on primary AML cells in vivo.
The double treatment is not mutagenic and might also prevent
the survival of AraC-derived mutated clones, reducing the
likelihood of relapse.
CHK1i plus AraC treatment does not affect normal HSPCs. It
is fundamental for new AML treatments to evaluate the effect of
the drug combination on normal human hematopoiesis. To
investigate this, we sorted CD34+ cells from human cord blood
(hCB) and injected them into NSG mice. When they reached
~70% human engraftment level, we divided the mice into four
groups and then followed the treatment regimen illustrated in
Fig. 4a. One week post treatment, a small but insigniﬁcant
decrease could be seen in human engraftment for all treatment
types compared to UT controls (Fig. 4b). We investigated this
small decrease further to analyze which hematopoietic sub-
population was most affected by the treatment. Hematopoietic
stem and progenitor cells (HSPCs, Lin−CD34+CD38−) were
importantly not affected by the double treatment (Fig. 4c),
whereas hematopoietic precursor cells (HPCs, Lin−CD34+CD38+)
showed a slight reduction in cell viability (Fig. 4d), even though
the difference between A+C and A-treated groups was not sig-
niﬁcant. Furthermore, we investigated whether the treatment
protocol could affect the long-term outlook of human hemato-
poiesis and therefore we killed the mice 8 weeks post treatment
and analyzed the human engraftment in the BMs. We found a
high percentage of human hematopoietic cells in all treatment
groups (Fig. 4e). Analysis of the HSPC and HPC compartments
showed that the percentage of HSPCs (Fig. 4f) and HPCs (Fig. 4g)
was not affected by the treatment. Furthermore, we studied the
functionality of the HSPCs after chemotherapy by performing
secondary transplantations. Eleven weeks post transplantation, we
checked the engraftment levels of secondary mice and actually
observed an increase in human cells in mice injected with A and
A+C group compared to UT and C groups (Fig. 4h). This result
suggests that the treatment of human hematopoietic cells in
primary mice selected for a quiescent population, which was
enriched in HSCs. Finally, considering that hCB HSCs present
different characteristics when compared to their human adult
bone marrow (hBM) counterparts, most importantly higher
proliferation rate29, 30, we decided to test the effect of the co-
treatment in mice engrafted with the more quiescent adult hBM
HSPCs. Following the previously described treatment protocol
(Fig. 4a), we saw no signiﬁcant decrease in the level of engraft-
ment in treatment groups 1 week post treatment compared to UT
controls (Supplementary Fig. 6A). Similar to hCB results, we did
not detect a signiﬁcant difference when comparing A-treated
mice to the A+C group, either at the HSPC level (Supplementary
Fig. 6B) or at the HPC level (Supplementary Fig. 6C). To inves-
tigate whether the chemotherapy could have affected the long-
term outlook of human hematopoiesis, we euthanized the mice
8 weeks post treatment. Once again, we found no signiﬁcant
difference among the treatment groups (Supplementary Fig. 6D),
at the HSPC (Supplementary Fig. 6E) or HPCs level (Supple-
mentary Fig. 6F).
In summary, addition of CHK1i to AraC treatment does not
impede normal long-term hematopoiesis derived from either hCB
or hBM cells.
G-CSF enhances the efﬁcacy of AraC+CHK1i on AML in vivo.
The addition of Chk1i considerably improves the primary effect
of AraC treatment for AML, but the remaining small fraction of
quiescent cells containing LICs must be eradicated to avoid the
possibility of relapse.
To test if these residual LICs survived because of their
quiescent state and not because of any other resistance
mechanisms, we decided to force these cells to cycle via the
administration of granulocyte colony-stimulating factor (G-CSF),
a well-known hematopoietic stem cell mobilizing agent31 as
previously described32. We thus established its mobilizing effect
on AML by treating the engrafted mice according to the scheme
in Supplementary Fig. 7A and analyzing BMs and blood 1 day
post treatment. In AML-engrafted mice, we observed a signiﬁcant
increase of human cells in the blood of G-CSF-treated mice
compared to UT but not in the BM (Supplementary Fig. 7B).
Moreover, we conﬁrmed that G-CSF was increasing the number
of proliferating AML cells and reducing the quiescent ones in the
BM (Supplementary Fig. 7C).
With these positive results, we introduced G-CSF to our
treatment regimen in combination with A+C treatment (A+C+G)
(Fig. 5a). Using this new treatment protocol, we tested four
primary AML patient samples, starting the treatment at HE, and
analyzed the human engraftment levels 1 week post treatment, as
previously described. Remarkably, we noticed that all AML-
engrafted mice were subject to a stronger leukemia reduction
when adding G-CSF to A+C treatment (Fig. 5b), including the
non-responder AML5 sample. AML7-engrafted mice offered a
remarkable example of nearly complete leukemic eradication after
A+C+G treatment, as shown by FACS (Fig. 5c). We noticed, by
IHC, that the small amounts of spared cells after the triple
treatment were still quiescent (Fig. 5d), suggesting that a longer
exposure to G-CSF might be needed. To assess the functionality
of those remaining cells, we performed either L-LTC-IC assay or
secondary mouse transplantation from the A+C- and A+C+G-
treated mice. We showed by the L-LTC-IC assay, a signiﬁcant
reduction in the stem cell frequency of A+C+G compared to A+C
from AML7 (Fig. 5e). For AML8, where we could perform
secondary transplantation, we detected around 40% engraftment
in the A+C group 12 weeks post injection, whereas no detectable
engraftment was seen in the A+C+G group (<0.01% detection
limit) (Fig. 5f).
All together, these data show that the addition of G-CSF to the
AraC+CHK1i combination therapy facilitates the elimination of the
quiescent LICs. These results also suggest that residual LICs are not
intrinsically resistant to AraC+CHK1i treatment, as when the LICs
are forced to cycle, they become sensitive and are eradicated.
AraC+CHK1i+G-CSF treatment does not affect normal
HSPCs. Lastly, we investigated whether the addition of G-CSF to
A+C would impede normal human hematopoieisis. We ﬁrst
conﬁrmed the mobilizing effect of G-CSF on both hCB and hBM
CD34+ cells following the treatment regimen in Supplementary
Fig. 7A by analyzing mouse BM and blood 1 day post treatment.
Although we did not observe a difference in terms of total
number of hematopoietic cells (hCB CD45+) in G-CSF-treated
mice compared to UT (Supplementary Fig. 7D), we found that
hCB HSPCs were mobilizing from the BM to the blood (Sup-
plementary Fig. 7E). Similar results were found when we trans-
planted the mice with the “less proliferative” hBM cells. Again, we
could observe a general mobilization of hBM CD45+ cells into the
blood (Supplementary Fig. 7F) and a clear shift of hBM HSPCs
from the bone marrow into the blood (Supplementary Fig. 7G).
Hence, we introduced G-CSF to our treatment regimen in com-
bination with A+C treatment (A+C+G) (Fig. 5a). We
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transplanted hBM CD34+ cells and started the treatment when
mice achieved ~70% human engraftment level. Upon A+C+G
treatment, we detected a signiﬁcant reduction of human cells
compared to A+C group, 1 week post treatment, but cells
recovered over a longer period of time (8 weeks post treatment)
(Fig. 5g). The functionality of the remaining human CD34+ cells
was tested by serial transplantation. We observed that cells
exposed to the triple treatment were able to engraft in secondary
mice at the same frequency as A+C and UT group (Supple-
mentary Table 5).
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These results suggest that even though G-CSF exhibits a
mobilizing effect on normal HSPCs, the triple therapy regimen
used in this study does not impede normal long-term
hematopoiesis.
Discussion
DNA damage checkpoints have recently drawn great interest as
strategic therapeutic targets given their crucial role in DNA
repair21–24. Our results show that CHK1 inhibition (with the
highly CHK1-selective small molecule inhibitor, GDC-0575)
extensively enhances the effect of the most efﬁcient DNA-
damaging agent used in the clinic for the cure of AML (AraC).
This chemo-potentiation strategy not only is beneﬁcial for the
increased clearance of AML, but it has implications for adding on
to treatment paradigms for elderly patients who cannot tolerate
high chemotherapy doses. Accordingly, in our xenograft models,
we used a 7-day treatment regimen of low-dose AraC (LDAC; 10
mg/kg), to mirror exposures reported in the clinic33 and com-
bined it with intermittent dosing of the CHK1i, to marked ben-
eﬁt. While our results broadly conﬁrm and extend conclusions
reached by other groups using AML cell lines21, 23, 24, 34, we have
used patient-derived samples and orthotopic engraftment, per-
mitting the assessment of treatment impact in a model system
with greater clinical relevance.
Our results are consistent with the ﬁrst phase 1 clinical report
using the combination AraC+CHK1i and showing the combi-
nation to be beneﬁcial and relatively well tolerated35.
In this study, our in vivo data suggest that the addition of
CHK1i has an enhancing effect only on AML patient samples that
are responsive to AraC treatment as a single agent. In fact, we
showed that the AML5 sample is quite resistant to AraC and the
addition of CHK1i has little additional effect. We suspect that
intrinsic chemoresistance is more likely due to defective cytar-
abine transport and/or metabolism in this patient, as suggested by
other published work36, 37. As this patient sample responded
better when G-CSF was added to AraC plus CHK1i, this indicates
that at least part of the resistance was due to the cell cycle status
of the cells.
Interestingly, AraC has been suggested to be mutagenic in most
AML patients25. In our in vivo models, we observed the gen-
eration of AraC-related de novo mutations only in one patient by
whole-exome sequencing. The difference in mutation burden
observed here might be due to differences in dosage of the drug
used or duration of treatment. Remarkably, the addition of
CHK1i to AraC treatment in our model prevented the survival of
mutagenic clones and thus the generation of new possible driving
mutations. The CHK1i itself did not exhibit mutagenic potential
in any of the three models tested. This ﬁnding highlights a per-
haps under-appreciated aspect of chemo-potentiation. By redu-
cing the threshold of DNA damage required for cell killing,
checkpoint abrogation strategies may reduce therapy-related
mutational load, thereby lowering the probability of acquired
resistance and/or generation of secondary cancers. Further ana-
lysis will be needed to conﬁrm our preliminary data.
Importantly, one of the main issues when testing new drugs is
their target speciﬁcity/off-target liabilities, which determines the
toxicity proﬁle for normal tissues and hematopoietic cells. In this
study, we show that intermittent GDC-0575 exposure, alone or in
combination with AraC, has little impact on normal long-term
hematopoiesis. Notably, we obtained the same results using both
cord blood-derived and adult bone marrow-derived hemato-
poietic cells, which are known to exhibit different cell cycle fea-
tures, among other properties. These data are encouraging to
clinical development plans, in that if mouse and human phar-
macokinetic proﬁles are similar, the AraC+CHK1i combination
promises to eradicate AML disease, while maintaining the
potential for a good bone marrow recovery.
Notably, our data with primary AML cells in vitro show that
the addition of CHK1i to AraC treatment is important for
enhancing the clearance of the bulk AML cells, but has little effect
on AraC-mediated LIC reduction. Moreover, cell cycle analysis
clearly showed enrichment in G0-phase cells after A and A+C
treatment, which suggests that human cells escaping the treat-
ment are quiescent and not exclusively enriched in LICs, in
accordance to what we previously described38. In support of these
results, the addition of CHK1i to AraC on primary AML models
in vivo, conﬁrmed the increased reduction in leukemic burden
but did not enhance the LIC’s depletion as demonstrated by the
similar reduced engraftment capacity between A and A+C in
secondary transplanted mice. This set of data also suggests that
LICs are not more quiescent than leukemic blasts but enter and
exit the cell cycle according to environmental signals.
In contrast, A and A+C treatment of normal hematopoietic
cells selects for quiescent HSCs, as supported by the higher
engraftment in secondary mice. These data, therefore, shed
light on a different balance between stemness vs. quiescence
between LICs and HSCs. It is indeed largely accepted that LICs,
like HSCs, are quiescent and their quiescence has become a
crucial therapeutic target39–41. Here we show that, differently
from HSCs, quiescence is not a characteristic sufﬁcient to select
for LICs.
Ultimately, in this study we also improved, in vivo, the efﬁcacy
of the A+C treatment by mobilizing, via G-CSF treatment, the
residual quiescent AML cell pool. The efﬁcacy of G-CSF in
improving chemotherapy has been controversial. One study
suggests that it signiﬁcantly enhances the elimination of human
primary AML stem cells in vivo32 but in another work, no evi-
dence of an increase in complete response rate in the presence of
G-CSF was observed42. Our data show that in our system the
addition of the mobilizer to the A+C therapy caused an almost
complete clearance of AML cells, including LICs, which lost their
engrafting capacity in secondary mice. Finally, the triple treat-
ment did not negatively impact normal long-term hematopoiesis
as it failed to affect the ability of HSCs to engraft in secondary
mice. We have therefore demonstrated a safe way to override
Fig. 5 G-CSF enhances the cytotoxicity of AraC+CHK1i on AML in vivo. a Treatment regimen for AraC, CHK1i, and G-CSF with primary AML samples and
normal hematopoietic cells, in vivo. b Percentage of human cells in the bone marrow of mice transplanted with four primary AML samples 1 week post
treatment. The treatment started at HE (gray area). Each dot represents an individual mouse. AML5 UT n= 5; A+C n= 4; A+C+G n= 3; AML6 UT n= 5; A
+C n= 6; A+C+G n= 5; AML7 UT n= 4; A+C n= 4; A+C+G n= 4; AML8 UT n= 3; A+C n= 4; A+C+G n= 3. Number of total mice= 50. c Percentage of
human cells in the bone marrow of AML7-transplanted mice 1 week post treatment. d Remaining leukemic cells in the bone marrow of AML7-transplanted
mice 1 week post treatment shown by hematoxilin & eosin (H&E, left panel) and immunoﬂuorescence (right panel). Green cells are human CD45+, red cells
are Ki67+, and nuclei are labelled blue. Scale bar is 100micron for all images. Lower graph represents the ratio of cycling Ki67+CD45+ cells. e L-LTC-IC
assay on hCD45+ cells pooled from AML7-injected mice 1 week post treatment. Cells were kept in vitro for 2 weeks in methylcellulose in a LDA assay.
Linear regression with 95% conﬁdence bands, (p value= 9.6−11. A+C n= 3; A+C+G n= 3). f Secondary transplantation of hCD45+ cells, pooled from
AML8-injected mice 1 week post treatment. Each dot represents an individual mouse (A+C n= 3; A+C+G n= 3). g Percentage of human cells in the bone
marrow of hBM-transplanted mice 1 week and eight weeks post treatment (UT n= 4; G n= 4). *p< 0.05 and ns= non-signiﬁcant
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concertedly both DNA repair and cell quiescence-mediated AraC
resistance in AML.
In summary, this study conducted in multiple clinically rele-
vant primary AML xenograft models, highlights the potential for
signiﬁcant clinical utility of LDAC/CHK1i regimens via reduction
of leukemic burden, potential elimination of de novo AraC-
mutated cells and enhanced patient survival.
Furthermore, the use of G-CSF to recruit quiescent AML into
cell cycle may accelerate the kinetics to achieve “minimal residual
disease” status, a triple combination therapy strategy that spares
normal long-term hematopoietic stem/progenitor cells (HSPCs)
and thereby improves patient recovery. The potential for GDC-
0575 as a safe and effective CHK1 inhibitor warrants further
investigation in LDAC/G-CSF combinations in the clinic.
Methods
Drug treatment. CHK1 inhibitor (GDC-0575) was kindly provided by Genentech.
For in vivo experiments, aliquots of GDC-0575 (10 mg/mL) were stored at −20 °C
and diluted in 100 mM sodium citrate buffer immediately prior to each experiment.
GDC-0575 was used at 1.8 mg/ml for female mice (~25 g) and 2.6 mg/ml for male
mice (~35 g) via oral gavage (ﬁnal concentration 7.5 mg/kg). For in vitro experi-
ments, aliquots of GDC-0575 (100 μM) were stored at −20 °C and used at a ﬁnal
concentration of 100 nM. AraC (Cytosine β-D-arabinofuranoside C1768, Sigma)
was used at 10 mg/kg (commonly used in clinical practice) for in vivo and at 100
nM and 500 nM for in vitro experiments. For in vivo experiments, toxicity of GDC-
0575 was assessed in non-engrafted NSG mice using a range of concentrations of
GDC-0575 in combination with AraC. 7.5 mg/kg GDC-0575 was the highest
concentration to have no signiﬁcant or lasting adverse effects in mice. Similarly, for
in vitro experiments, 100 nM GDC-0575 in combination with 500 nM AraC was
the highest concentration non-cytotoxic to MS5 stoma cell. ATR inhibitor (AZ 20,
Tocris, Bristol, UK) was used at a ﬁnal concentration of 0.5 μM.
RNA silencing. For silencing of Chk1 expression, two lentiviral vectors were
purchased from VectroBuilder, one shRNA against CHK1 (5′-GCAA-
CAGTATTTCGGTATAAT-3′) and one shRNA against LacZ used as a control (5′-
GTCGGCTTACGGCGGTGATTT-3′). Lentivirus was produced from these con-
structs by transient calcium phosphate-mediated transfection of 293T cells with the
lentiviral backbone plasmid, a vsv-g encoding plasmid and a gag/pol plasmid. Virus
supernatants were concentrated by ultracentrifugation to achieve titers of 1 × 109
IU/ml.
AML cell lines and primary cell co-cultures. HL60, KG-1, ML1, U937 AML cell
lines and MS-5 feeder cells were originally obtained through ATCC and main-
tained by the Francis Crick Institute Cell Bank. Each cell line was validated by short
tandem repeat (STR) proﬁling using the PowerPlex 16HS system. AML cell lines
were cultured in RPMI 1640 containing 10% heat-inactivated FBS, 2% penicillin,
and streptomycin at 37 °C in 5% CO2/95% air. MS-5 feeder cells were cultured in
IMDM containing 10% heat-inactivated FBS, 2% penicillin, and streptomycin at
37 °C in 5% CO2/95% air. MS-5 cells were subcultured when reaching 80% con-
ﬂuency. An antibody against mouse Sca-1 (BD Pharmingen, Oxford Science Park,
UK) was used to identify the feeder. Primary AML cells were grown in Myelocult
H5100 medium (StemCell Technologies, Vancouver) supplemented with 20 ng/ml
IL-3, 20 ng/ml G-CSF and 20 ng/ml TPO (PeproTech, London, UK). For co-culture
experiments, 2 days before initiating the co-culture, feeder cells were plated onto
type-I collagen-coated 96-well or 6-well plates (Falcon) and allowed to reach
conﬂuence. One day before starting co-culture, they were irradiated at 6.8 Gy and
the culture media exchanged. On day 0 of the co-culture, AML cells were plated at
2 × 105 cells/ml using the correspondent AML medium. Cells were cultured at 37 °
C in 5% CO2-humidiﬁed incubators at indicated oxygen concentrations. For short-
term culture (STC), cells were kept for 1 week in hypoxia (5% O2) with the
indicated drugs: 500 nM AraC and/or 100 nM GDC-0575 (Genentech). For long-
term culture/limiting dilution assay (LTC/LDA), human cells from STC were
magnetically sorted using hCD45 via the StemSep system (Stem Cell Technologies)
according to the manufacturer’s instructions and plated on a freshly prepared
irradiated MS-5 layer at the indicated concentrations. They were cultured in
normoxic conditions with no addition of drug for 4 weeks and half medium
changes were performed once a week without disrupting the established feeder
layer.
Primary AML, cord blood and bone marrow cells. AML samples were obtained
after informed consent at St Bartholomew’s Hospital (London, UK). The cells were
collected and frozen at diagnosis. Details of patient samples are provided in Sup-
plementary Table 1. AML mononuclear cells (MNCs) were isolated by cen-
trifugation using Ficoll-Paque (GE Healthcare Life Sciences, Buckinghamshire,
UK). Before using AML MNCs, we performed an immuno-magnetic T-cell
depletion by the Easysep T-cell enrichment cocktail (StemCell Technologies,
Vancouver, Canada). Umbilical cord blood (UCB) samples were obtained from
normal full-term deliveries after signed informed consent. Both AML and UCB
samples collection were approved by the East London Research Ethical Committee
(REC: 06/Q0604/110) and in accordance with the Declaration of Helsinki. MNCs
were puriﬁed by Ficoll-Paque density centrifugation (GE Healthcare Life Sciences,
Buckinghamshire, UK) and ammonium chloride red cell lysis. Density-separated
cord blood mononuclear cells were magnetically sorted for CD34 via the StemSep
system (Stem Cell Technologies) according to the manufacturer’s instructions to
generate CD34+ cells. Adult bone marrow (BM) CD34+ cells were purchased
directly from Lonza (Lonza, Basel, Switzerland).
Establishment of AML models in immunodeﬁcient mice. AML cell line (2 × 106
cells/mouse), primary AML samples (105 to 2 × 106 cells/mouse), hCB CD34+ (1 ×
105 cells/mouse), and hBM CD34+ (3 × 105 cells/mouse) were transplanted into
8–12 weeks old female or male NOD-SCID IL2Rγnull (NSG) mice (The Jackson
laboratory, Bar Harbor, ME, USA) using intravenous injection. Twenty-four hours
before transplantation, mice were sublethally irradiated at the dose of 3.75 Gy. To
assess the level of engraftment, BM samples were aspirated from a long bone while
mice were under isoﬂurane anesthesia, at different time points after transplanta-
tion. After the establishment of engraftment (8–12 weeks), mice were randomized
into different treatment groups based on the level of engraftment of each mouse so
that each group of mice have the same mean level of human CD45+CD33+ cells.
The investigator was thus not blinded to the group allocation. Mice were treated
with drugs according to the experimental design. For secondary transplant, mouse
BMs of the same experimental condition were pooled and human CD45+ cells were
sorted. 0.5−1 × 106 cells were transplanted into secondary sublethally irradiated
NSG mice. All animal work was done under the project license (PPL 70/8904)
approved by the UK Home Ofﬁce and following the CRUK guidelines.
Flow cytometry and cell sorting. For analysis and sorting of AML and HSPCs
derived from hCB or adult BM, cells were stained with hCD45-PeCy7(Clone: H30,
cat: 560915, dilution 1 in 25), mCD45-PerCPCy5.5 (Clone:30-F11, cat: 550994,
dilution 1 in 400), Lineage-FITC (lin1, cat: 340546, 1 in 25), CD34-PE (Clone 581,
cat: 560941, dilution: 1 in 25), and CD38-APC (Clone HIT2, cat: 555462; dilution:
1 in 25) (BD Biosciences, Oxford, UK). Human grafts in mice were assessed using
CD19-FITC (Clone: H1B19; cat: 555412, dilution: 1 in 25), CD33-PE (Cat: WM53,
cat: 555450, dilution 1 in 25), CD3-APC (Clone: UCHT1, cat: 561811, dilution: 1 in
25), hCD45-PeCy7 (Clone: H30, cat: 560915, dilution 1 in 25), and mCD45-
PerCPCy5.5 (Clone:30-F11, cat: 550994, dilution 1 in 400) (BD Biosciences).
Luciferase-transduced HL60 and U937 cells were identiﬁed and sorted based on
their GFP expression. Non-viable cells were excluded by DAPI staining. Appro-
priate isotype-matched antibodies were used as controls. Flow cytometry analysis
was performed using an LSRII ﬂow cytometer (BD Biosciences). Cell sorting was
performed using a FACS Aria or INFLUX (BD Biosciences).
Bioluminescence imaging. Isoﬂuorane-anesthetized animals were imaged using
the Xenogen IVIS imaging system 5–10 min after D-luciferin (Caliper Life Sciences,
Cambridge, UK) was injected intraperitoneally (150 mg/kg). Bioluminescence
images were taken from both ventral and dorsal sides of the mice. The photons
emitted from HL60-Luc and U937-Luc, expressed as Flux (photons/s/cm2/ster-
adian), were quantiﬁed and analyzed using the “Living image” software (Caliper
Life Science).
Cell proliferation by XTT assay. AML cell lines were seeded at 1 × 104 cells/well
in 96-well plates in triplicate, and subjected to different treatment conditions. After
24 h of incubation, cell proliferation was measured with the XTT Cell Proliferation
Kit II (Roche, Mannheim, Germany) in accordance with the manufacturer’s pro-
tocol. The spectrophotometric absorbance of each well was determined using a
SPECTRA max PLUS 384 (Molecular Devices, Sunnyvale, CA). The wavelength for
measuring absorbance was 450 nm and the reference wavelength was 650 nm.
Apoptosis assay. AML cell lines were seeded at 2 × 105 cells/well in 24-well plates
in triplicate. After 24 h of incubation with various drugs, Annexin V labeling was
used to quantify the effects of treatment on apoptosis. Thirty microliters of 10×
Annexin V binding buffer (BD Pharmingen) were added to 270 μl of the resus-
pended cells and mixed. Then, 2 μl of directly conjugated Annexin V Alexa Fluor
647 (Molecular Probes) was added to the cells before incubation at 37 °C for 15
min. DAPI was added to the cells before analysis on a BD LSR-2 ﬂow cytometer.
Cell cycle. Intracellular immuno-staining for Ki67 was used to determine the cell
cycle status. AML cells from co-cultures were ﬁrst incubated with anti-human
CD45-PeCy7 (Clone: H30, cat: 560915, dilution 1 in 25) and Sca-PE (Clone: D7,
Cat: 553108, dilution 1 in 400) antibodies (BD Biosciences, Oxford, UK), washed
with PBS, ﬁxed in 1 ml of PBS with 2% methanol-free formaldehyde at room
temperature (RT) for 10 min and washed twice with PBS. Cells were then per-
meabilized with 1 ml of PBS containing 0.1% Triton-X-100 (TX; Sigma, Dorset,
UK) for 10 min at RT. After washing, cells were incubated with Alexa Fluor 647-
Ki67 antibody (eBioscience, San Diego, USA) at 4 °C for 1 h. Cells were
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resuspended with PBS 2% FBS buffer containing DAPI (2 mg/ml) and analyzed by
FACS.
Immunoﬂuorescence. AML cell lines were allowed to attach to poly-L-lysine-
coated slides for 30 min. They were then ﬁxed with 4% paraformaldehyde at RT for
10 min, permeabilized with PSB/0.1% TX for 10 min, blocked with 10% serum
(donkey or goat) for 30 min at RT, incubated with primary antibodies at 4 °C
overnight (O/N) and then with appropriate secondary antibodies for 1 h at RT.
Slides were mounted with ﬂuorescence mounting medium (Dako, Cambridgeshire,
UK) containing DAPI for nuclear staining. Sections were then visualized using a
ﬂuorescent microscope (Zeiss AxioVision2; Zeiss, Welwyn Garden City, UK).
Images were acquired using Axiocam MRC with Axiovision 4.7 software. Anti-
bodies used: γH2Ax (05-636, Millipore), CHK1Ser345 (133D3, Cell Signaling
Technology).
Immunohistochemistry. Spinal column samples were harvested, formalin-ﬁxed,
and decalciﬁed with 17% EDTA (Osteosoft, Millipore) during 7 days. Then samples
were processed, parafﬁn embedded, and transverse sectioned (5 µm) for histolo-
gical studies. Hematoxylin/eosin staining, immunohistochemestry (IHC), and
immunoﬂuorescence (IF) studies were performed by standard methods. For IHC
and IF, heat-induced antigen retrieval was performed when required. Primary
unconjugated antibodies employed were anti-Ki67 (Abcam, Ab16667), and anti-
humanCD45 (Dako, M0701). Secondary ﬂuorescent antibodies were from Invi-
trogen and secondary biotinylated antibodies were from Jackson. After IF, slices
were treated with Sudan black 0.1% to reduce auto-ﬂuorescence in bone marrow
tissue.
Western blot analysis. Total protein extracts (20 μg) were run on a denaturing
10% SDS-polyacrylamide electrophoresis (PAGE) gel and transferred by wet
transfer to nitrocellulose membranes. The primary antibodies used were CHK1 (sc-
22799), CDC25A (sc-7389) from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), CHK1 Ser345 (133D3), CHK1 Ser296 (90178), pTyr15 CDK2 (9111), and
GAPDH (2118) from Cell Signaling Technology, Danvers, MA, USA), CDK2
(010145) from BioScience and pCDC25A (156574) from Abcam. Protein bands
were visualized using an enhanced chemiluminescence visualization system (ECL
Plus, Amersham Life Sciences).
Chemotherapy treatment of in vivo models. NSG mice were injected intrave-
nously with 1 × 105–106 cells of AML and 1–3 × 105 cells of hCB CD34+/hBM
CD34+. After demonstrating AML engraftment at 9–11 weeks through FACS
analysis of tibia bone marrow aspiration, mice were treated accordingly to proper
7-day treatment regimen with daily 10 mg/kg AraC via subcutaneous injection, 7.5
mg/kg CHK1i suspension administered via oral gavage on every other day sche-
dule, and/or 300 μg/kg G-CSF (Chugai Pharma UK) administered daily for 5 days
via intraperitoneal injection. One week after the ﬁnal dosing, mice were killed by
cervical dislocation. The femurs, tibias, and pelvis were dissected and ﬂushed with
PBS. Red blood cells were lyzed via ammonium chloride. Cells were stained with
human-speciﬁc FITC-conjugated anti-CD19, PE-conjugated anti-CD33, PE-Cy7-
conjugated anti-CD45, and PERCP-conjugated anti-murine CD45 antibodies.
Dead cells and debris were excluded via DAPI staining. A BD LSR II ﬂow cyt-
ometer was used for analysis. Flow cytometry analysis was performed with FlowJo
software (Tree Star, Oten, Switzerland). More than 100,000 DAPI-negative events
were collected. Engraftment of AML was said to be present if a single population of
mCD45−hCD45+CD33+CD19− cells was present without accompanying mCD45
−hCD45+CD33−CD19+cells.
Statistical analysis. Statistical analyses were performed using GraphPad Prism
Version 6.0 f (GraphPad Software). Error bars indicate the SEM of data from
replicate experiments. The signiﬁcance of difference between samples within ﬁg-
ures was conﬁrmed using multivariable one-way ANOVA unpaired analysis cor-
rected for multiple comparisons. Observed differences were regarded as statistically
signiﬁcant if the calculated p value was below 0.05. *p < 0.05; **p< 0.001; ***p<
0.0001; ****p < 0.00001. For xenotransplantation analysis, a non-parametric
Mann–Whitney unpaired test was applied.
Whole-genome ampliﬁcation. Whole-genome ampliﬁcation (WGA) of cells from
mice was performed using illustra Single Cell GenomiPhi DNA Ampliﬁcation Kit
(GE Healthcare Life Sciences). WGA ampliﬁcation was performed according to the
manufacturer's instructions along with a negative control with no DNA and a
reaction with human tissue genomic DNA as a positive control.
Whole-exome sequencing and data analysis. Three AML patients were selected
for whole-exome sequencing (WES), using DNA from day 0 CD33+ cells (primary
bone marrow sample) in all cases and DNA from CD3+ T cells as a paired con-
stitutional DNA source. In addition, DNA from CD45+CD33+ cells derived from
mice following xenotransplantation were also subjected to WES analysis. WES was
only performed in mice where enough xenografted cells were recovered (three
patient samples transplanted into 34 mice). qDNA (non-WGA, 100 ng) or WGA
DNA (500 ng) was processed for exome library capture (Agilent SureSelect V5) and
sequenced on the Illumina HiSeq2500 (Paired end V4 chemistry) according to the
manufacturer’s instructions. Initially, base calling was performed by the Illumina
RTA software (Supplementary Fig. 6). Demultiplexing and conversion of basecalls
to fastq ﬁles was performed by Casava version 1.8.2. Data alignment, realignment,
and recalibration were performed using Burrows–Wheelers aligner (BWA-MEM
v0.7.12)43 and GATK44, 45, respectively; according to Broad Institute best practices.
VarScan (v2.4.146, 47 was subsequently used to perform somatic variant calling on
mpileup ﬁles generated by Samtools48 for paired tumor and normal (CD3+ T cells)
tissue as well as for xenografted samples. Following on, data were then passed
through ANNOVAR49 using refseq annotation and variants not found in
dbSNP138 and 1000 genomes databases at >0.01 population allele frequency were
passed. Genomic duplicated regions were also ﬁltered out unless associated with
known mutations. Somatic mutations were subsequently passed when somatic p
value (VarScan, Fisher’s exact t-test) was <0.01, had ≥7 supporting reads, were
present in paired normal tissue at less than 20% of the paired tumor tissue and had
a allele burden of >5%.
Stringent secondary analysis was performed to obtain high conﬁdence single-
nucleotide variants (mutations). For xenografted CD45+CD33+ cells, candidate
mutations were only scored if they were present in more than one mouse within
the same treatment category, and/or found concurrently in Day 0 sample or any of
the untreated mice for the same patient. Variants with homopolymer runs of ﬁve or
more ﬂanking the mutation were also ﬁltered out. Variant that are present in genes
which are frequently mutated in myeloid malignancies were included in the ﬁnal
list even if they failed any of the above-mentioned data ﬁltering criteria.
Exome coverage. Exome coverage was calculated utilizing GATK DepthOf-
Coverage against intervals that the Agilent V5 Sureselect kit capture probes were
based on. Mean base coverage across the targeted region ranged from 10–281 X
and for >90% of the exome base coverage was >10 reads in all cases (apart from
one WGA t-cells) (Supplementary Table 4).
Data availability. The majority of data generated or analyzed during this study are
included in this published article (and its supplementary information ﬁles). Others
are available from the corresponding author on reasonable request. The NGS data
generated in this study are deposited in the European Nucleotide Archive
(ENA) under the accessible code (Study: PRJEB23171- project: enba-STUDY-
Francis Crick Institute-20-10-2017-16:34:55:352-226).
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